HOTH
Hoth Therapeutics Inc (HOTH)
Healthcare • NASDAQ • $0.67-3.44%
- Symbol
- HOTH
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.67
- Daily Change
- -3.44%
- Market Cap
- $12.82M
- Trailing P/E
- N/A
- Forward P/E
- -0.94
- 52W High
- $2.12
- 52W Low
- $0.49
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.58
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical t…
Company websiteResearch HOTH on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.